Literature DB >> 9364685

Twenty-three-year follow-up study of rubella antibodies after immunization in a closed population, and serological response to revaccination.

T Asahi1, K Ueda, Y Hidaka, C Miyazaki, Y Tanaka, S Nishima.   

Abstract

Twenty-six institutionalized children immunized with a Japanese rubella vaccine, Matsuba strain, have been observed for 23 years and the persistence of vaccine-induced rubella immunity documented. All vaccinees were shown to have seroconverted to rubella virus in a haemagglutination inhibition (HI) test, and the geometric mean titre (GMT) of rubella HI antibody rose to 2 5-8 months after vaccination (Ueda et al., Acta Paediatrica Japonica, Overseas Edition 1978, 20, 8-14). The GMT then declined gradually to 2 23 years after inoculation, except in four cases (15.4%) which had reverted to negative. However, three of the four maintained a rubella HI antibody titre of 1:4. Twelve of the 26 vaccinees were revaccinated 24 years after primary vaccination, and all ten cases having initial titres of < or = 1:16 demonstrated secondary responses. Rubella immunity induced by vaccination had persisted, so routine booster immunization did not seem necessary. However, a second immunization programme should be considered to achieve high antibody-positive rates and to protect against primary vaccine failure.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9364685     DOI: 10.1016/s0264-410x(97)00114-x

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  2 in total

1.  Placental transfer of maternal rubella antibodies to full-term and preterm infants.

Authors:  N Linder; L Sirota; Y Aboudy; B German; T Lifshits; B S Barnea; B Lieberman; E Mendelson; A Barzilai
Journal:  Infection       Date:  1999 May-Jun       Impact factor: 3.553

2.  How useful is a history of rubella vaccination for determination of disease susceptibility? A cross-sectional study at a public funded health clinic in Malaysia.

Authors:  Ai Theng Cheong; Seng Fah Tong; Ee Ming Khoo
Journal:  BMC Fam Pract       Date:  2013-01-31       Impact factor: 2.497

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.